Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 8/20 | 0.39 |
| ▸ | HTR2C | P28335 | 8/20 | 0.39 |
| ▸ | HTR2B | P41595 | 5/20 | 0.39 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.36 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.36 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3049331 | 0.89 | TBXA2R (0.39) | HTR2AHTR2CHTR2BSLC5A2P2RX4 | |
| SCHEMBL3040972 | 0.81 | LTB4R (0.41) | — | |
| SCHEMBL3047763 | 0.73 | SLC5A1 (0.45) | HTR2AHTR2CHTR2BSLC5A2SLC5A1 | |
| SCHEMBL3410215 | 0.73 | TSPO (0.42) | LMNAPOLB | |
| SCHEMBL3049904 | 0.72 | BCHE (0.43) | SLC5A2BCHE | |
| SCHEMBL3048236 | 0.71 | LTB4R (0.39) | POLB | |
| SCHEMBL3045532 | 0.63 | HTR2C (0.55) | HTR2AHTR2CHTR2BSLC5A2SLC5A1 | |
| SCHEMBL1539188 | 0.63 | KEAP1 (0.70) | — | |
| SCHEMBL31024314 | 0.63 | HTR2A (0.62) | HTR2AHTR2CHTR2B | |
| SCHEMBL23120104 | 0.63 | HTR2C (0.46) | HTR2AHTR2CHTR2BPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820630-B2 | Substituted indole-O-glucosides | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-26 | — | — | US | disclosed |
| US-20100009900-A1 | SUBSTITUTED INDOLE-O-GLUCOSIDES | BEAVERS MARY PAT | 2010-01-14 | — | — | US | disclosed |
| EP-1680131-A4 | SUBSTITUTED INDOLE-O-GLUCOSIDES | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-27 | — | — | EP | disclosed |
| US-20090105164-A1 | SUBSTITUTED INDOLE-O-GLUCOSIDES | BEAVERS MARY PAT | 2009-04-23 | — | — | US | disclosed |
| US-7511022-B2 | Substituted indole-O-glucosides | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-31 | — | — | US | disclosed |
| US-20060293251-A1 | Substituted indazole-O-glucosides | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-28 | — | — | US | disclosed |
| US-7129220-B2 | Substituted indole-O-glucosides | JANSSEN PHARMACEUTICA N.V (BE) | 2006-10-31 | — | — | US | disclosed |
| EP-1680131-A2 | SUBSTITUTED INDOLE-O-GLUCOSIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-19 | — | — | EP | disclosed |
| US-20050037981-A1 | Substituted indole-O-glucosides | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-17 | — | — | US | disclosed |
| WO-2005012243-A2 | SUBSTITUTED INDOLE-O-GLUCOSIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009900-A1 | SUBSTITUTED INDOLE-O-GLUCOSIDES | GPR119, PYGL, IAPP | HTR2A 168/4885HTR2C 267/4885HTR2B 188/4885 |
| US-20090105164-A1 | SUBSTITUTED INDOLE-O-GLUCOSIDES | GPR119, PYGL, IAPP | HTR2A 168/4885HTR2C 267/4885HTR2B 188/4885 |
| US-20050037981-A1 | Substituted indole-O-glucosides | GPR119, PYGL, IAPP | HTR2A 168/4885HTR2C 267/4885HTR2B 188/4885 |
| US-20060293251-A1 | Substituted indazole-O-glucosides | GPR119, PYGL, GYS2 | HTR2A 1089/4885HTR2C 786/4885HTR2B 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.